Novo Nordisk A/S

NYSE:NVO

Drug Manufacturers - General

Healthcare
$39.43 -1.09%

-$0.48 today

Market cap
$173.82B
Beta
0.35
P/E (TTM)
10.2
EPS (TTM)
$27.45
Dividend yield
4.18%
52W Low $35.12High $74.38

Volume 16.12M

Average 16.05M

NVO Free Cash Flow

Operating cash flow minus capital expenditures: cash available for debt repayment, dividends, and buybacks.

Novo Nordisk A/SNYSE: NVO

Free Cash Flow · Q2 FY2026 · quarter ended Jun 2026

Free cash flow growth accelerates

Q2 FY2026 free cash flow of DKK 42.4B rose 73.0% year over year, ahead of the -20.6% change in trailing-twelve-month free cash flow. Sequentially, it rose 252.0% from the prior quarter. Over 3 fiscal years it compounded at -23.3% a year.

Context

  • Free cash flow amounted to 9.4% of revenue in FY2025, down 14.6 pp from a year earlier.
  • Free cash flow increased in 1 of the last 3 fiscal years.
  • FY2025 was the lowest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly growth of +73.0% holds above the trailing-twelve-month pace of -20.6%.

Sources:Cash FlowText generated from reported figures; not investment advice.

Latest quarterJun 2026
DKK 42.4B+252.0% QoQ
Last fiscal yearDec 2025
DKK 28.99B-58.4% YoY
LTMJun 2026
DKK 48.92B-20.6% YoY
Free Cash Flow past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+73.0%——
1 year-58.4%——
3-year CAGR-23.3%——
5-year CAGR——
10-year CAGR——

Free Cash Flow history

DKK · from the cash flow

Latest · FY2025
28.99B DKK
Year-over-year change
-58.4%
4-year CAGR
-11.7%

Free Cash Flow vs competitors

How NVO compares with its peers on the latest reported figures

  • Peers report in different currencies, so free cash flow is compared through growth and share of revenue rather than absolute size.
  • Its year-over-year change of -20.6% is the lowest of 10, against a peer median of +7.9%.
  • Free cash flow amounts to 14.8% of revenue for NVO, versus a peer median of 24.1%.
NVO Competitors
Free Cash Flow for NVO and competitors
Company Period LTM YoY 3-year CAGR% of revenue
NVONovo Nordisk A/SLTM Jun 2026DKK 48.92B DKK-20.6%-23.3%14.8%
JNJJohnson & JohnsonLTM Sep 2026$20.59B USD+7.9%+4.7%20.7%
LLYEli Lilly and CompanyLTM Jun 2026$20.05B USD+40048.0%+24.9%25.2%
ABBVAbbVie Inc.LTM Jun 2026$18.21B USD-0.2%-9.8%28.3%
MRKMerck & Co., Inc.LTM Jun 2026$16.06B USD+9.1%-5.6%24.2%
SNYSanofiLTM Jun 2026€11.77B EUR+462.3%+6.4%24.1%
PFEPfizer Inc.LTM Jun 2026$10.99B USD-11.7%-29.6%17.2%
AMGNAmgen Inc.LTM Jun 2026$10.18B USD-4.1%-2.7%26.7%
AZNAstraZeneca PLCLTM Sep 2026$9.32B USD-2.6%+6.2%15.0%
GSKGSK plcLTM Jun 2026£6.98B GBP+49.6%-4.8%21.0%
Peer median (excluding NVO) —+7.9%-2.7%24.1%

Competitors are the stored peer set for NVO. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Cash Flow Statement

DKK
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Net Income47.76B55.53B83.68B100.99B102.43B
Depreciation & Amortization6.03B7.36B9.41B19.11B21.98B
Deferred Income Tax11.32B13.54B20.99B26.2B28.11B
Stock-Based Compensation1.04B1.54B2.15B2.29B0
Change in Working Capital(8.66B)(5.54B)(12.25B)2.59B3.74B
Accounts Receivables(12.91B)(10.82B)(14.21B)(14.31B)0
Inventory(1.09B)(4.77B)(7.42B)(9.04B)0
Accounts Payables3.15B6.72B10.02B3.24B0
Other Working Capital2.19B3.34B(631M)22.7B3.74B
Other Non-Cash Items(2.49B)6.46B4.92B(30.21B)(37.16B)
Operating Cash Flow55B78.89B108.91B120.97B119.1B
Capital Expenditures(7.39B)(14.75B)(38.9B)(51.31B)(90.11B)
Acquisitions (Net)(18.28B)(7.08B)0(82.16B)1B
Purchases of Investments(7.11B)(9.74B)(13.29B)(19.81B)(723M)
Sales of Investments1.17B6.65B8.29B24.39B10.67B
Other Investing Activities4M(2.61B)(13.09B)(4.15B)(29.97B)
Investing Cash Flow(31.61B)(24.92B)(43.89B)(128.9B)(79.16B)
Debt Repayment15.47B(2.41B)(1.47B)73.06B24.74B
Common Stock Issued00000
Common Stock Repurchased(19.45B)(24.09B)(29.92B)(20.18B)(1.39B)
Dividends Paid(21.52B)(25.3B)(31.77B)(44.14B)(51.76B)
Other Financing Activities00000
Financing Cash Flow(25.49B)(51.8B)(63.16B)8.74B(28.41B)
Effect of Forex Changes591M(238M)(119M)455M(727M)
Net Change in Cash(1.51B)1.93B1.74B1.26B10.81B
Free Cash Flow47.62B64.13B70.01B69.66B28.99B

Novo Nordisk A/S

NYSE:NVO

Intrinsic Alpha fair value

Locked

Current Price

$39.43

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.